| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
13,030,000 |
| Market
Cap: |
62.02(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.05 - $22.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 634 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Eagle Pharmaceuticals is a pharmaceutical company focused on developing medicines to treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. Co.'s products include: Belrapzo® (bendamustine ready-to-dilute (RTD) 500ml solution), Bendeka® (infused bendamustine RTD) and Treakisym® for chronic lymphocytic leukemia and non-hodgkin's lymphoma; Ryanodex® (dantrolene sodium) for malignant hyperthermia; EP-4104 Ryanodex® (dantrolene sodium) for the treatment of organophosphate exposure; PEMFEXY™ (pemetrexed for injection) for lung cancer; and EA-114 (fulvestrant) for breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
20,245 |
87,045 |
| Total Sell Value |
$0 |
$0 |
$300,027 |
$1,741,115 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
2 |
7 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schreiber Alain |
10% Owner |
– – • |
2016-06-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(9,903) |
5,582 |
|
- |
|
| Proquest Financial Llc |
10% Owner |
– – • |
2016-05-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,360 |
|
- |
|
| Proquest Financial Llc |
10% Owner |
– – • |
2016-05-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,770,828 |
|
- |
|
| Schreiber Alain |
Director |
– • • |
2016-05-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,780,188) |
9,360 |
|
- |
|
| Schreiber Alain |
Director |
– • • |
2016-05-13 |
4 |
S |
$40.92 |
$572,062 |
I/I |
(13,980) |
41,081 |
|
- |
|
| Schreiber Alain |
Director |
– • • |
2016-05-12 |
4 |
S |
$40.00 |
$160,000 |
I/I |
(4,000) |
55,061 |
|
- |
|
| Tarriff Scott |
President and CEO |
• • – |
2016-04-01 |
4 |
AS |
$40.63 |
$1,249,982 |
D/D |
(30,765) |
1,369,946 |
|
- |
|
| Graves Michael |
Director |
– • – |
2016-03-15 |
4 |
B |
$56.73 |
$56,730 |
D/D |
1,000 |
1,000 |
2.39 |
- |
|
| Tarriff Scott |
President and CEO |
• • – |
2016-03-01 |
4 |
AS |
$62.70 |
$1,250,028 |
D/D |
(19,780) |
1,400,711 |
|
- |
|
| Tarriff Scott |
President and CEO |
• • – |
2016-02-01 |
4 |
AS |
$66.03 |
$1,249,974 |
D/D |
(18,360) |
1,420,491 |
|
- |
|
| Tarriff Scott |
President and CEO |
• • – |
2016-01-04 |
4 |
AS |
$85.65 |
$1,249,921 |
D/D |
(14,549) |
1,438,851 |
|
- |
|
| Flaum Sander A |
Director |
– • – |
2015-12-22 |
4 |
S |
$93.76 |
$302,360 |
D/D |
(3,225) |
16,374 |
|
- |
|
| Tarriff Scott |
President and CEO |
• • – |
2015-12-01 |
4 |
AS |
$86.92 |
$1,249,419 |
D/D |
(14,050) |
1,453,400 |
|
- |
|
| Tarriff Scott |
President and CEO |
• • – |
2015-11-02 |
4 |
AS |
$64.07 |
$1,249,955 |
D/D |
(19,339) |
1,467,450 |
|
- |
|
| Tarriff Scott |
President and CEO |
• • – |
2015-10-01 |
4 |
AS |
$68.50 |
$1,249,965 |
D/D |
(17,878) |
1,486,789 |
|
- |
|
| Tarriff Scott |
President and CEO |
• • – |
2015-09-01 |
4 |
AS |
$75.12 |
$1,249,998 |
D/D |
(16,245) |
1,504,667 |
|
- |
|
| Tarriff Scott |
President and CEO |
• • – |
2015-08-03 |
4 |
AS |
$95.39 |
$1,250,408 |
D/D |
(13,000) |
1,520,912 |
|
- |
|
| Schreiber Alain |
Director |
– • • |
2015-07-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,970) |
59,061 |
|
- |
|
| Tarriff Scott |
President and CEO |
• • • |
2015-07-01 |
4 |
AS |
$77.58 |
$1,248,855 |
D/D |
(15,710) |
1,533,912 |
|
- |
|
| Krill Steven L. |
Chief Scientific Officer |
• – – |
2015-06-16 |
4 |
S |
$81.60 |
$814,368 |
D/D |
(9,980) |
0 |
|
- |
|
| Krill Steven L. |
Chief Scientific Officer |
• – – |
2015-06-16 |
4 |
OE |
$4.42 |
$81,520 |
D/D |
9,980 |
1,400 |
|
- |
|
| Schreiber Alain |
Director |
– • • |
2015-05-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(9,903) |
62,031 |
|
- |
|
| Flaum Sander A |
Director |
– • – |
2015-03-20 |
4 |
S |
$42.00 |
$411,600 |
D/D |
(9,800) |
19,599 |
|
- |
|
| Tarriff Scott |
President and CEO |
• • • |
2015-03-20 |
4 |
AS |
$42.00 |
$5,040,000 |
D/D |
(120,000) |
1,549,622 |
|
- |
|
199 Records found
|
|
Page 8 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.21%) 
